二甲双胍对精神科肥胖患者糖脂代谢的影响

Effects of metformin on glucose and lipid metabolism of psychiatric patients with obecity

目的:观察二甲双胍对精神科肥胖患者糖脂代谢的影响。方法:120例需要抗精神病药维持治疗的精神科肥胖患者随机分为研究组和对照组各60例。研究组给予二甲双胍0.75g/d治疗6个月;对照组不予干预直接随访。于治疗前和治疗后3个月和6个月测定身高、体质量、空腹血糖(FBS)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)。结果:完成119例,研究组60例,对照组59例。研究组和对照组在治疗6个月时FBS(t=-2.650,P=0.009)、HbA1c(t=-3.615,P=0.000)、HDL(F=9.365,P=0.003)减分值比较,差异均有统计学意义;而FINS、LDL和TG减分值两组比较差异均无统计学意义(P均>0.05)。结论:二甲双胍能降低精神科肥胖患者的FBS、HbA1c,升高HDL。

Objective： To observe the effect of metformin on glucose and lipid metabolism of psychiatric patients with obecity. Method： 120 subjects with obesity were randomly divided into two groups（ study group and control group）. The study group（60 subjects） recieved metformin 0.75 g/day treatment for 6 months and the control group （60 subjects） received non-intervention follow-up. The height, weight, fasting blood sugar （ FBS）, triglyceride （ TG）, high density lipoprotein （ HDL）, low densitylipoprotein （ LDL）, glycated hemoglobin （HbA1c）, fastinginsulin （FINS）were measured at baseline and at the end of 3,6 months. Results： 119 patients were completed the study with 60 patients in the study group and 59 patients in the control group;There were significant differences on FBS,HbAlc,HDL reducing scores at the end of 6 months between the study group and the control group （ t = - 2. 650, P = 0. 009 ）, （ t = - 3.615, P = 0. 000）, （ F = 9. 365, P = 0.003 ） respectively, but no differences on FINS,LDL and TG reducing scores （all P 〉 0. 05 ）. Conclusion ： Metformin can reduce FBS, HbAlc and increase HDL of the psychiatric patients with obesity.